Review



rantes response (ccr5  (DiscoverX corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    DiscoverX corporation rantes response (ccr5
    Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
    Rantes Response (Ccr5, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rantes response (ccr5/product/DiscoverX corporation
    Average 90 stars, based on 1 article reviews
    rantes response (ccr5 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade"

    Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

    Journal: Molecular pharmacology

    doi: 10.1124/mol.111.071985

    Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
    Figure Legend Snippet: Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.

    Techniques Used: Activation Assay, Concentration Assay, Mutagenesis, Transfection

    Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).
    Figure Legend Snippet: Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).

    Techniques Used: Mutagenesis, Screening Assay

    Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.
    Figure Legend Snippet: Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.

    Techniques Used: Beta-Arrestin Assay, Activation Assay, Concentration Assay



    Similar Products

    rantes response (ccr5  (DiscoverX corporation)
    90
    DiscoverX corporation rantes response (ccr5
    Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
    Rantes Response (Ccr5, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rantes response (ccr5/product/DiscoverX corporation
    Average 90 stars, based on 1 article reviews
    rantes response (ccr5 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.

    Journal: Molecular pharmacology

    Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

    doi: 10.1124/mol.111.071985

    Figure Lengend Snippet: Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.

    Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

    Techniques: Activation Assay, Concentration Assay, Mutagenesis, Transfection

    Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).

    Journal: Molecular pharmacology

    Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

    doi: 10.1124/mol.111.071985

    Figure Lengend Snippet: Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).

    Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

    Techniques: Mutagenesis, Screening Assay

    Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.

    Journal: Molecular pharmacology

    Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

    doi: 10.1124/mol.111.071985

    Figure Lengend Snippet: Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.

    Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

    Techniques: Beta-Arrestin Assay, Activation Assay, Concentration Assay